Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Racial Differences in Hepatitis C Virus (HCV)/Host Interactions Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Racial Differences in Hepatitis C Virus (HCV)/Host Interactions conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Racial Differences in Hepatitis C Virus (HCV)/Host Interactions Clinical research trials and Racial Differences in Hepatitis C Virus (HCV)/Host Interactions healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Racial Differences in Hepatitis C Virus (HCV)/Host Interactions. Racial Differences in Hepatitis C Virus (HCV)/Host Interactions Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Racial Differences in Hepatitis C Virus (HCV)/Host Interactions clinical trial. Subjects frequently obtain the most expert healthcare possible for their Racial Differences in Hepatitis C Virus (HCV)/Host Interactions condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "R" Clinical Trials Conditions > Racial Differences in Hepatitis C Virus (HCV)/Host Interactions

Racial Differences in Hepatitis C Virus (HCV)/Host Interactions



Racial Differences in Hepatitis C Virus (HCV)/Host Interactions

For Condition: Hepatitis C
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of the research study is to evaluate a group of African Americans and Caucasians with hepatitis C virus (HCV) infection and compare their response rates to treatment with a combination of pegylated interferon and ribavirin.
Details: The purpose of this study is to identify causes for racial differences in response to therapy for treatment of HCV. This will involve examining differences between racial groups in the hepatitis virus, how the body processes the medications and the genetic makeup of persons. The patients will be taking standard treatment - a combination of pegylated interferon alpha 2b and ribavirin for either 24 or 48 weeks. Clinic visits and blood samples will be at study entry and 1, 2, 4 and 8 weeks after beginning treatment and then once a month until medication is stopped. Subjects will have clinic visits for 6 months after completion of therapy.
Eligibility:
Study Type:  Interventional, Treatment, Non-Randomized, Uncontrolled, Single Group Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: - Adult, male or female, African American or Caucasian, age of 18 or older and never been treated wtih interferon or ribavirin. - Serum positive for hepatitis C virus by PCR or other assays (e.g., bDNA). - Liver biopsy within 2 years of entry to protocol. - Compensated liver disease with the laboratory parameters: Hemoglobin values of >= 12gm/dL for females OR >= 13gm/dL for males; Neutrophil count >= 1500/mm3; platelets >= 85000/mm3; Albumin > 3.0 mg/dL; serum creatinine <=1.4 mg/dL; Thyroid stimulating hormone within normal limits of thyroid disease under control. EXCLUSION CRITERIA: - Hypersensitivity to alpha interferon or ribavirin. - Hemoglobinopathies. - Evidence of advanced liver disease. - Patients with evidence of ischemia. - Patients wtih clinically significant retinal abnormalities. - Active substance abuse, such as alcohol, intravenous (IV) and inhaled drugs. - Patients with history of organ transplantation. - Patients infected with HIV. - Preexisting severe psychiatric conditions.
Total Enrollment: 125

Location and Contact Information:

University of Tennessee Helath Science Ctr. *Recruiting*
Memphis,  Tennessee,  38163
United States
Recruiting  


Additional Information:
Study ID Numbers:  00-091; 
Study Start Date: March 2001
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071916

Other Hepatitis C Studies:
1. Phase III Randomized Study of High vs Standard Dose of Interferon alfa for Chronic Hepatitis C

2. Hepatitis C Antiviral Resistance in African-Americans

3. History of Hepatitis C in Volunteer Blood Donors

4. Peginterferon alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

5. Treatment of Cholestatic Pruritus With Sertraline

Related Studies:

Other Hepatitis C Clinical Trials
Other Tennessee Clinical Trials
Other Memphis Clinical Trials

Racial Differences in Hepatitis C Virus (HCV)/Host Interactions
Modify your Search

  Other Hepatitis C Clinical Trials
  Other Tennessee Clinical Trials
  Other Memphis Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103